AAAAAA
Results: 26-44/44
Authors:
Davis, TA
Grillo-Lopez, AJ
White, CA
McLaughlin, P
Czuczman, MS
Link, BK
Maloney, DG
Weaver, RL
Rosenberg, J
Levy, R
Citation: Ta. Davis et al., Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:Safety and efficacy of re-treatment, J CL ONCOL, 18(17), 2000, pp. 3135-3143
Authors:
Liao, ZX
Ha, CS
McLaughlin, P
Manning, JT
Hess, M
Cabanillas, F
Cox, JD
Citation: Zx. Liao et al., Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmaticpresentation: Natural history and patterns of disease progression, INT J RAD O, 48(2), 2000, pp. 399-403
Authors:
Anderlini, P
Giralt, S
Andersson, B
Ueno, NT
Khouri, I
Acholonu, S
Cohen, A
Korbling, MJ
Manning, J
Romaguera, J
Sarris, A
Rodriguez, MA
Hagemeister, F
McLaughlin, P
Cabanillas, F
Champlin, RE
Citation: P. Anderlini et al., Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease, BONE MAR TR, 26(6), 2000, pp. 615-620
Authors:
McLaughlin, P
Hagemeister, FB
Rodriguez, MA
Sarris, AH
Pate, O
Younes, A
Lee, MS
Dang, NH
Romaguera, JE
Preti, AH
McAda, N
Cabanillas, F
Citation: P. Mclaughlin et al., Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma, SEMIN ONCOL, 27(6), 2000, pp. 37-41
Authors:
McLaughlin, P
Khawaja, M
Citation: P. Mclaughlin et M. Khawaja, The organizational dynamics of the US environmental movement: Legitimation, resource mobilization, and political opportunity, RURAL SOCIO, 65(3), 2000, pp. 422-439
Authors:
McLaughlin, P
Citation: P. Mclaughlin, Diagnosis treatment, BR DENT J, 189(5), 2000, pp. 235-235
Authors:
Donato, ML
Champlin, RE
Van Besien, KW
Korbling, M
Cabanillas, F
Anderlini, P
Gajewski, JG
Lauppe, J
Durett, A
Andersson, B
Giralt, S
Khouri, I
Hagemeister, F
Romaguera, JE
Sarris, A
McLaughlin, P
Younes, A
Ippoliti, C
Blamble, DA
Hester, J
Gee, A
Rodriguez, MA
Citation: Ml. Donato et al., Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma, LEUK LYMPH, 35(3-4), 1999, pp. 317-324
Authors:
Perez, N
Garcier, JM
Pin-Leveugle, J
Lhoste-Trouilloud, A
Ravel, A
McLaughlin, P
Viallet, JF
Boyer, L
Citation: N. Perez et al., Dynamic magnetic resonance imaging of the female pelvis: radio-anatomy andpathologic applications. Preliminary results, SUR RAD AN, 21(2), 1999, pp. 133-138
Authors:
Sarris, AH
Kliche, KO
Pethambaram, P
Preti, A
Tucker, S
Jackow, C
Messina, O
Pugh, W
Hagemeister, FB
McLaughlin, P
Rodriguez, MA
Romaguera, J
Fritsche, H
Witzig, T
Duvic, M
Andreeff, M
Cabanillas, F
Citation: Ah. Sarris et al., Interleukin-10 levels are often elevated in serum of adults with Hodgkin'sdisease and are associated with inferior failure-free survival, ANN ONCOL, 10(4), 1999, pp. 433-440
Authors:
McLaughlin, P
Citation: P. Mclaughlin, Inroads in the therapy of indolent lymphomas: Exploiting biological insights, CANCER INV, 17(1), 1999, pp. 73-86
Authors:
Yao, JC
Thomakos, N
McLaughlin, P
Buchholz, TA
Kudelka, AP
Citation: Jc. Yao et al., Tamoxifen-induced thrombocytopenia, AM J CL ONC, 22(5), 1999, pp. 529-532
Authors:
Romaguera, JE
Rodriguez, MA
Hagemeister, FB
McLaughlin, P
Rodriguez, J
Preti, A
Younes, A
Sarris, AH
Cabanillas, F
Citation: Je. Romaguera et al., Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/Mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination, INV NEW DR, 17(2), 1999, pp. 187-192
Authors:
McLaughlin, P
Hagemeister, FB
Grillo-Lopez, AJ
Citation: P. Mclaughlin et al., Rituximab in indolent lymphoma: The single-agent pivotal trial, SEMIN ONCOL, 26(5), 1999, pp. 79-87
Authors:
Lopez-Guillermo, A
Cabanillas, F
McDonnell, TI
McLaughlin, P
Smith, T
Pugh, W
Hagemeister, F
Rodriguez, MA
Romaguera, JE
Younes, A
Sarris, AH
Preti, HA
Lee, MS
Citation: A. Lopez-guillermo et al., Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma, BLOOD, 93(9), 1999, pp. 3081-3087
Authors:
Rodriguez, J
McLaughlin, P
Hagemeister, FB
Fayad, L
Rodriguez, MA
Santiago, M
Hess, M
Romaguera, J
Cabanillas, F
Citation: J. Rodriguez et al., Follicular large cell lymphoma: An aggressive lymphoma that often presentswith favorable prognostic features, BLOOD, 93(7), 1999, pp. 2202-2207
Authors:
Rodriguez, J
Rodriguez, MA
Fayad, L
McLaughlin, P
Swan, F
Sarris, A
Romaguera, J
Andersson, B
Cabanillas, F
Hagemeister, FB
Citation: J. Rodriguez et al., ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease, BLOOD, 93(11), 1999, pp. 3632-3636
Authors:
Romaguera, JE
Hagemeister, FB
McLaughlin, P
Rodriguez, MA
Bachier, C
Preti, H
Sarris, AH
Weber, D
Younes, A
Cabanillas, F
Citation: Je. Romaguera et al., Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesnaand consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma, LEUK LYMPH, 32(1-2), 1998, pp. 97-106
Authors:
McLaughlin, P
White, CA
Grillo-Lopez, AJ
Maloney, DG
Citation: P. Mclaughlin et al., Clinical status and optimal use of rituximab for B-cell lymphomas, ONCOLOGY-NY, 12(12), 1998, pp. 1763-1769
Authors:
Younes, A
Romaguera, J
Mesina, O
Hagemeister, F
Sarris, AM
Rodriguez, MA
McLaughlin, P
Preti, HA
Bachier, C
Cabanillas, F
Citation: A. Younes et al., Paclitaxel plus high-dose cyclosphosphamide with G-CSF support in patientswith relapsed and refractory aggressive non-Hodgkin's lymphoma, BR J HAEM, 103(3), 1998, pp. 678-683